Literature DB >> 23053649

E-cadherin promotor methylation and mutation are inversely related to motility capacity of breast cancer cells.

Remco van Horssen1, Antoinette Hollestelle, Joost A P Rens, Alexander M M Eggermont, Mieke Schutte, Timo L M Ten Hagen.   

Abstract

Inactivation of the tumor suppressor E-cadherin is an important event during breast tumorigenesis, as its decreased expression is linked to aggressiveness and metastasis. However, the relationship between the different modes of E-cadherin inactivation (mutation versus promotor hypermethylation) and breast cancer cell behavior is incompletely understood. The high correlation between E-cadherin inactivation status and cell morphology in vitro suggests different biological roles for the two inactivation modes during breast tumorigenesis. Because E-cadherin has been linked to cell invasion and metastasis, and cell motility is a crucial prerequisite to form metastases, we here compared the cell motility capacities of breast cancer cell lines with known E-cadherin status. Using barrier migration assays and time-lapse microscopy, we analyzed the migratory capacity of nine well-characterized human breast cancer cell lines (MDA-MB-231, MCF-7, T47D, BT549, MPE600, CAMA-1, SUM159PT, SUM52PE, and SK-BR-3). This subset was chosen based on E-cadherin gene status (wild-type, mutated, and promotor hypermethylated): three cell lines of each group. In addition, cell proliferation assays were performed for all conditions, to dissect migratory from proliferative effects. In this study, we demonstrate an overt association between the mode of E-cadherin inactivation and cell migration. Promotor hypermethylated E-cadherin cell lines showed a higher migration capacity, while cell lines with mutated E-cadherin were less motile compared to wild-type E-cadherin cell lines. Migration induction by fibronectin and basic fibroblast growth factor did not alter the cell motility association differences. Cell proliferation assays showed that the associations found were not caused by proliferation differences. Inhibition and overexpression of E-cadherin as well as DNA demethylation confirmed the relationship between E-cadherin and breast cancer cell motility. Our results demonstrate an association between the mode of E-cadherin inactivation and migration of breast cancer cells, which justifies more detailed research on the role of E-cadherin inactivation in cell migration and metastasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23053649     DOI: 10.1007/s10549-012-2261-8

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  13 in total

1.  A ring barrier-based migration assay to assess cell migration in vitro.

Authors:  Asha M Das; Alexander M M Eggermont; Timo L M ten Hagen
Journal:  Nat Protoc       Date:  2015-05-21       Impact factor: 13.491

2.  DNA methylation of E-cadherin is a priming mechanism for prostate development.

Authors:  Kimberly P Keil; Lisa L Abler; Vatsal Mehta; Helene M Altmann; Jimena Laporta; Erin H Plisch; M Suresh; Laura L Hernandez; Chad M Vezina
Journal:  Dev Biol       Date:  2014-02-03       Impact factor: 3.582

3.  Physical Mechanisms of Cancer in the Transition to Metastasis.

Authors:  Pilhwa Lee; Charles W Wolgemuth
Journal:  Biophys J       Date:  2016-07-12       Impact factor: 4.033

4.  Homeoprotein Six2 promotes breast cancer metastasis via transcriptional and epigenetic control of E-cadherin expression.

Authors:  Chu-An Wang; David Drasin; Catherine Pham; Paul Jedlicka; Vadym Zaberezhnyy; Michelle Guney; Howard Li; Raphael Nemenoff; James C Costello; Aik-Choon Tan; Heide L Ford
Journal:  Cancer Res       Date:  2014-10-27       Impact factor: 12.701

Review 5.  Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises.

Authors:  Nikolaos Garmpis; Christos Damaskos; Anna Garmpi; Emmanouil Kalampokas; Theodoros Kalampokas; Eleftherios Spartalis; Afrodite Daskalopoulou; Serena Valsami; Michael Kontos; Afroditi Nonni; Konstantinos Kontzoglou; Despina Perrea; Nikolaos Nikiteas; Dimitrios Dimitroulis
Journal:  Cancer Genomics Proteomics       Date:  2017 Sep-Oct       Impact factor: 4.069

6.  MiR-199a-5p loss up-regulated DDR1 aggravated colorectal cancer by activating epithelial-to-mesenchymal transition related signaling.

Authors:  Yingbin Hu; Jingshi Liu; Bonian Jiang; Juying Chen; Zhongpin Fu; Fei Bai; Jiarui Jiang; Ziyuan Tang
Journal:  Dig Dis Sci       Date:  2014-04-08       Impact factor: 3.199

7.  CDH1 promoter methylation correlates with decreased gene expression and poor prognosis in patients with breast cancer.

Authors:  Jian Liu; Xin Sun; Sida Qin; Huangzhen Wang; Ning DU; Yanbo Li; Yamei Pang; Cuicui Wang; Chongwen Xu; Hong Ren
Journal:  Oncol Lett       Date:  2016-02-24       Impact factor: 2.967

8.  MicroRNA-30a increases tight junction protein expression to suppress the epithelial-mesenchymal transition and metastasis by targeting Slug in breast cancer.

Authors:  Chia-Wei Chang; Jyh-Cherng Yu; Yi-Hsien Hsieh; Chung-Chin Yao; Jui-I Chao; Po-Ming Chen; Hsiao-Yen Hsieh; Chia-Ni Hsiung; Hou-Wei Chu; Chen-Yang Shen; Chun-Wen Cheng
Journal:  Oncotarget       Date:  2016-03-29

9.  Diagnostic impact of promoter methylation and E-cadherin gene and protein expression levels in laryngeal carcinoma.

Authors:  Katarzyna Starska; Ewa Forma; Iwona Lewy-Trenda; Paweł Papież; Jan Woś; Magdalena Bryś
Journal:  Contemp Oncol (Pozn)       Date:  2013-06-28

10.  E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition.

Authors:  Augustine Chen; Henry Beetham; Michael A Black; Rashmi Priya; Bryony J Telford; Joanne Guest; George A R Wiggins; Tanis D Godwin; Alpha S Yap; Parry J Guilford
Journal:  BMC Cancer       Date:  2014-07-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.